Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

OTHER 15INDUSTRY 2NIH 1

Study Type

Interventional 2

Sponsor

Conditions

Arthritis, Rheumatoid 2

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × Abatacept × Clear all
NCT01350804 2016-05-23

NURTURE 1

Novartis

Phase 3 Completed
551 enrolled 19 charts

Arthritis, Rheumatoid

NCT00048581 2011-11-21

Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past.

Bristol-Myers Squibb

Phase 3 Completed
738 enrolled 84 charts

Arthritis, Rheumatoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡